Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
257 results about "Natriuretic peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A natriuretic peptide is a peptide which induces natriuresis- the excretion of sodium by the kidneys.
Natriuretic polypeptides
ActiveUS7754852B2Peptide/protein ingredientsTissue cultureIntensive care medicineLower blood pressure
This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing natriuretic activities within a mammal.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Conjunctive analysis of biological marker expression for diagnosing organ failure
InactiveUS6461828B1Easy to useHigh riskAnalysis using chemical indicatorsEnzymologyOrgan systemOrganism
A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.
Owner:SYN X PHARMA
Method and composition for treatment of skeletal dysplasias
InactiveUS7276481B2Improve stabilityEnhance NP stabilizationPeptide/protein ingredientsGenetic material ingredientsBone growthBULK ACTIVE INGREDIENT
The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for achondroplasia. The effects of the natriuretic peptide may be further enhanced by prolonging its residence time or action at the target site.
Owner:HEPACORE LTD
Human brain natriuretic peptides
The present invention provides reagents and assays for the quantification of hBNP in biological fluid samples such as plasma or serum. Antibodies are provided which are monospecific to epitopes comprising the amino acid sequences 5-13, 1-10 and 15-25 of hBNP. These antibodies, and peptide fragments containing these sequences, can be employed in the assays of the invention, which may be carried out in a sandwich format or a competition format.
Owner:SCIOS
Polypeptides related to natriuretic peptides and methods of their identification and use
InactiveUS7341838B2Prevent degradationThe result is accurateCompound screeningApoptosis detectionTissue sampleEvent triggered
The present invention relates to the identification and use of polypeptides that bind to antibodies directed to a desired polypeptide of interest. Using natriuretic peptides and their precursors, and in particular BNP, as an example, the present invention describes a number of natriuretic peptides fragments produced in biological samples, most preferably blood-derived samples, that bind to antibodies directed to BNP. Because production of such fragments is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the elapsed time between sample acquisition and the time the sample is analyzed; the type of tissue sample at issue; the storage conditions; the quantity of proteolytic enzymes present; etc., such fragments may be used when both designing an assay for one or more natriuretic peptides, and when performing such an assay, in order to provide an accurate prognostic or diagnostic result.
Owner:VERMILLION INC +1
Methods And Compositions For Monitoring And Risk Prediction In Cardiorenal Syndrome
ActiveUS20080254485A1Reduce riskIncreased riskMicrobiological testing/measurementDisease diagnosisMedicineMortality rate
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
Owner:ALERE SAN DIEGO INC
Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides
InactiveUS20120220528A1Lower elevated filing pressureImproves dyspneaPeptide/protein ingredientsPharmaceutical delivery mechanismNephrosisNephropathy
Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either an external or implantable programmable pump.
Owner:CAPRICOR THERAPEUTICS
Methods for treating congestive heart failure
InactiveUS20050113286A1Avoid deathPreventing hospitalizationPeptide/protein ingredientsDepsipeptidesCongestive heart failure chfIntensive care medicine
The present invention relates to methods for administration of natriuretic peptide that are especially useful for treatment of a CHF patient. The methods are characterized by the serial and intermittent administration of a composition that provides a dose of natriuretic peptide. The methods of the invention are also useful for the treatment of chronic CHF patients, especially chronically decompensated CHF patients.
Owner:SCIOS
Method for treating cardiac remodeling following myocardial injury
InactiveUS20060019890A1Improve heart functionWorsen cardiac functionPeptide/protein ingredientsDepsipeptidesDiseaseHeart disorder
The invention concerns methods for treating cardiac remodeling in a subject who has undergone myocardial injury, said method comprising the administration of natriuretic peptide to said subject. Preferably the natriuretic peptide is brain natriuretic peptide. The invention also concerns methods for treating structural heart disorders arising from myocardial injury, said method comprising the administration of a natriuretic peptide to a patient in need thereof.
Owner:SCIOS
Methods and compositions for the diagnosis of diseases of the aorta
InactiveUS20070224643A1Facilitate patient treatmentConvenient treatmentDiagnosticsSurgeryAortic dissectionSmooth Muscle Myosins
The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and / or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP79-108, BNP3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I, free and complexed cardiac troponin I, free cardiac troponin T, complexed cardiac troponin T, and free and complexed cardiac troponin T, and preferred assays are configured to detect these markers.
Owner:BIOSITE INC
Variants of C-Type Natriuretic Peptide
ActiveUS20100297021A1Improve the immunityReduce functionBacteriaPeptide/protein ingredientsDiseaseSmooth muscle
The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
Owner:BIOMARIN PHARMA INC
Long lasting natriuretic peptide derivatives
InactiveUS20050176641A1High activityProlong half-life in vivoBiocidePeptide/protein ingredientsVascular diseaseBlood component
This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having an extended in vivo half-life, and method for the treatment of cardiovascular diseases and disorders such as acute decompensated congestive heart failure (CHF) and chronic CHF.
Owner:CONJUCHEM BIOTECH INC
Proteinaceous compounds and uses therefor
ActiveUS20080153747A1Useful profiles of bioactivityAntibacterial agentsPeptide/protein ingredientsDiuresisMedicine
The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.
Owner:QUEENSLAND THE UNIV OF +1
Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
The present invention describes compositions and methods designed to determine the presence or amount of biologically active natriuretic peptides, or their fragments, in a sample. The degradation of natriuretic peptides is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the quantity of proteolytic enzymes present; etc. This degradation can produce circulating amounts of natriuretic peptides having reduced or lost biological function. The present invention provides, inter alia, assays designed to accurately measure biologically active natriuretic peptides, and compositions to inhibit a previously unknown pathway for degradation of natriuretic peptides.
Owner:BIOSITE INC
Variants of C-type natriuretic peptide
ActiveUS8198242B2Improve the immunityReduce functionPeptide/protein ingredientsMuscular disorderDiseaseSmooth muscle
Owner:BIOMARIN PHARMA INC
Natriuretic fusion proteins
Natriuretic peptide fusion proteins comprising natriuretic peptides linked to antibody Fc domains, nucleic acid molecules encoding the fusion proteins disclosed herein, expression vectors expressing said fusion proteins, pharmaceutical compositions comprising said fusion proteins, and methods for their therapeutic use are disclosed.
Owner:BOEHRINGER INGELHEIM INT GMBH +1
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
InactiveUS7917208B2Reduce frequencyHigh sensitivityElectrocardiographyHeart defibrillatorsMicrocontrollerCardioversions
Medical device and methods are provided for controlled drug delivery in a cardiac patient. The device includes an implantable drug delivery module comprising reservoirs containing a drug and a control means for selectively releasing an effective amount of drug from each reservoir; one or more electrodes or sensors for cardiac monitoring, stimulation, or both; and a microcontroller for controlling operational interaction of the drug delivery module and the cardiac electrode. The electrodes may comprise ECG monitoring, cardioversion, or cardiac pacing electrodes. A medical device also is provided for controlled delivery of drug to a patient having congestive heart failure, which includes an implantable drug delivery module comprising a natriuretic peptide and a release mechanism for selectively releasing a pharmaceutically effective amount of the natriuretic peptide into the patient; and a microcontroller for controlling the release mechanism, for example, in response to one or more monitored patient parameters.
Owner:MICROCHIPS BIOTECH INC
Apparatus and method for transdermal delivery of natriuretic peptides
InactiveUS20060034903A1Prevent oxidationImprove stabilityPeptide/protein ingredientsMicroneedlesMedicineBiocompatible coating
An apparatus and method for transdermally delivering a natriuretic peptide comprising a delivery system having a microprojection member that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the natriuretic peptide is contained in a biocompatible coating that is applied to the microprojection member. In a further embodiment, the delivery system includes a natriuretic peptide-containing hydrogel formulation. In an alternative embodiment, the natriuretic peptide is contained in both the coating and the hydrogel formulation. In yet another embodiment, the natriuretic peptide is contained in a solid state formulation.
Owner:ALZA CORP
Adenovirus vectors encoding brain natriuretic peptide
The invention provides isolated and purified nucleic acid molecules encoding a natriuretic peptide useful in methods to inhibit or prevent heart failure.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Type v phosphodiesterase inhibitors and natriuretic polypeptides
InactiveUS20070042957A1Enhances renal effectImprove kidney functionOrganic active ingredientsPeptide/protein ingredientsIntensive care medicineNatriuretic peptide
This document provides methods and materials related to PDE V inhibitors, natriuretic polypeptides, and combinations thereof. For example, compositions containing one or more PDE V inhibitors in combination with one or more natriuretic polypeptides are provided herein. In addition, methods for using PDE V inhibitors, natriuretic polypeptides, and combinations thereof to influence heart or renal activities within a mammal are provided herein.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Method and composition for treatment of skeletal dysplasias
InactiveUS20080194682A1Improve stabilityEnhance NP stabilizationPolypeptide with localisation/targeting motifBiocideFactor iiBULK ACTIVE INGREDIENT
Owner:HEPACORE LTD
Immunoassays for human brain natriuretic peptide
Immunoassays and antibodies useful in conducting them for human and canine brain natriuretic peptide are described.
Owner:SCIOS
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
ActiveUS20130323244A1Reduced dose-dependent side effectPeptide/protein ingredientsHydrolasesDiseaseNeurofibromatosis type I
The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes, disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.
Owner:VANDERBILT UNIV +1
Assessing risk of cardiac intervention based on gdf-15
ActiveUS20110065204A1Analysis using chemical indicatorsComponent separationRisk of mortalityNatriuretic peptide
The present invention relates to a method of identifying a subject being susceptible to a cardiac intervention based on the determination of GDF-15 in a sample of a subject in need of a cardiac intervention. Moreover, the present invention pertains to a method for predicting the risk of mortality or a further acute cardiovascular event for a subject suffering from a cardiovascular complication based on the determination of GDF-15 and a natriuretic peptide and / or a cardiac troponin in a sample the said subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.
Owner:MEDIZINISCHE HOCHSCHULE HANNOVER
Materials and Methods for Treatment of Allergic Diseases
InactiveUS20080070858A1Inhibit synthesisOrganic active ingredientsPeptide/protein ingredientsBiologyDisease cause
The present invention pertains to a method for treatment of allergic diseases by administering a natriuretic hormone peptide (NHP), or a nucleic acid sequence encoding NHP, to a patient in need thereof. In another aspect, the present invention concerns an expression vector comprising a nucleic acid sequence encoding NHP. In another aspect, the present invention concerns a host cell genetically modified with a nucleic acid sequence encoding NHP. In another aspect, the present invention concerns a pharmaceutical composition comprising NHP or a nucleic acid sequence encoding NHP and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to novel fragments of atrial natriuretic peptide (ANP) exhibiting bronchodilatory and anti-inflammatory activity, and isolated nucleic acid sequences encoding the fragments.
Owner:UNIV OF SOUTH FLORIDA
Diuretic and natriuretic polypeptides
InactiveUS20100204094A1Increasing diuretic activityIncreasing natriuretic activityPharmaceutical delivery mechanismSkeletal disorderMammalIntensive care medicine
This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and / or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and / or natriuretic activities within a mammal.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Treatment or prophylaxis of ischemic heart disease
InactiveUS7026293B2Increase intracellular cGMP productionReduced areaHormone peptidesPeptide/protein ingredientsReperfusion injuryIschemic necrosis
The present invention provides a pharmaceutical composition and a method for reducing an infarct region resulting from the ischemic necrosis of cells, especially, a pharmaceutical composition and a method for suppressing ischemia-reperfusion injury in the treatment of ischemic heart disease. The pharmaceutical composition and the method utilize a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has the effect of reducing an infarct region. The substance is preferably a natriuretic peptide. The present invention is particularly useful for the treatment or prophylaxis of ischemic disease.
Owner:KITAKAZE MASAFUMI
Stable calibrators or controls for measuring human natriuretic peptides
ActiveUS20050014287A1Present invention remain stableEnzymologyBiological testingMedicineNatriuretic peptide
Owner:ABBOTT LAB INC
Conjunctive analysis of biological marker expression for predicting cardiac mortality
InactiveUSRE39816E1Replace expensive and time-consumingEfficient use ofAnalysis using chemical indicatorsEnzymologyOrgan systemMortality rate
Owner:NEXUS DX
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com